Tracer library / [177Lu]Lu-P17-088

[177Lu]Lu-P17-088

Also written as [177Lu]Lu-P17-088; [Lu-177]Lu-P17-088

Radionuclide: Lu-177 t½ 9585 min
Modality: Therapy
Production route: —
Stage: Clinical research
Syntheses indexed: 2

Prostate cancer PSMA-directed radioligand therapy

What it is

Compound class: PSMA-targeted small-molecule radioligand
Target / mechanism: Prostate specific membrane antigen (PSMA) PMID 41249585
Clinical application: PSMA-targeted radioligand therapy for metastatic castrate resistant prostate cancer under clinical investigation in China PMID 41249585
Theranostic pair: —

Published syntheses

Module	Cassette	Purification	Yield %	RCP %	Precursor / supplier	Source
MiniLu	custom manifold	none	~95%	~99%	P17-088 Five Eleven Pharma	41249585 2025 EJNMMI Radiopharm Chem a new cassette-based, radiosynthesis platform named MiniLu™ - A final product yield (activity in dose vial / starting Lu-177 activity) of ~ 95% was achieved after formulation with L-ascorbate and gentisic acid (15 mL) and sterile filtration using MiniLu™ and the simulated high activity conditions for both compounds.
MiniLu in-house	custom manifold	none	~95%	99%	P17-088 Five Eleven Pharma	41249585 2025 EJNMMI Radiopharm Chem a custom-made, cassette-based box named MiniLu™ - A final product yield (activity in dose vial / starting Lu-177 activity) of ~ 95% was achieved after formulation with L-ascorbate and gentisic acid (15 mL) and sterile filtration using MiniLu™ and the simulated high activity conditions for both compounds.

Clinical literature

Clinical studies in the indexed corpus, ordered by design (multicentre, prospective, retrospective, others, case reports last) and then by year. Titles and links only, as published; this is not a summary of the evidence.

Comparison of novel PSMA-targeting [177Lu]Lu-P17-087 with its albumin binding derivative [177Lu]Lu-P17-088 in metastatic castration-resistant prostate cancer patients: a first-in-human study.
2024 · Eur J Nucl Med Mol Imaging · Clinical study

Precursor

Common precursor: —
Suppliers seen in the literature: —
Cited suppliers in indexed syntheses: Five Eleven Pharma
Typical final purification: —

Need this precursor?We can point you to suppliers for [177Lu]Lu-P17-088, or handle the enquiry for you.

Get in touch

Quality control Preliminary - inferred from compound class

Ph. Eur. monograph: not verified No Ph. Eur. check is recorded for this entry.
USP monograph: not verified No USP check is recorded for this entry.

AppearancepHRCP HPLCHPLC UVRadionuclidic (HPGe)Half-lifeActivityEndotoxins (LAL)SterilityFilter integrityOsmolalityMolar activityMetal impuritiesLu-177m

How this set was arrived at. base set per Ph. Eur. general monograph 0125 (rule); radiometal tracer -> metal impurities (rule); Lu-177 preparation -> Lu-177m content (rule); therapeutic radiopharmaceutical -> osmolality (rule); receptor ligand with a saturable target -> molar activity (rule)

Tests listed by reference only. Monograph texts are copyrighted and are not reproduced here. How these are derived

Setting up quality control?We can help you scope the equipment needed to release [177Lu]Lu-P17-088.

Get in touch

Notes

Added from reverse module search (stage 6); 1 article(s) with Lu-177. Stage set/updated at stage 23 from PMID 41249585: '[177Lu]Lu-P17-087 and [177Lu]Lu-P17-088 are new prostate specific membrane antigen (PSMA) targeted drugs under clinical investigation in China.'. | Stage 30 (2026-09-18): Stage was 'clinical investigation'; normalised to 'Clinical research', original wording kept here.